Zenocutuzumab, an investigational bispecific antibody, has shown early efficacy in an ongoing phase I/II study of patients with tumors harboring NRG1 fusions. The data so far appear particularly promising in NRG1 fusion–positive pancreatic ductal adenocarcinoma, which tends to occur in younger patients.

©2021 American Association for Cancer Research.
2021
American Association for Cancer Research.
You do not currently have access to this content.